An update from Polyrizon Ltd. ( (PLRZ) ) is now available.
Polyrizon Ltd. announced the successful completion of a preliminary safety study for its PL-14 Allergy Blocker, conducted on April 25, 2025. The study, which used a human nasal tissue model, demonstrated strong local tolerability and no signs of inflammatory activation, marking a significant step in the product’s development. This milestone supports Polyrizon’s regulatory strategy and prepares the company for upcoming FDA meetings and clinical trials in the U.S. and Europe, expected to commence in late 2025 or early 2026.
More about Polyrizon Ltd.
Polyrizon Ltd. is a development stage biotech company that specializes in creating innovative intranasal hydrogels. These hydrogels are delivered as nasal sprays and form a protective barrier in the nasal cavity to shield against viruses and allergens. The company’s proprietary technology, Capture and Contain, acts as a ‘biological mask’ and is also being developed for drug delivery applications.
YTD Price Performance: -80.93%
Average Trading Volume: 287,124
Technical Sentiment Signal: Strong Buy
For a thorough assessment of PLRZ stock, go to TipRanks’ Stock Analysis page.